异喹胍的氧化多态性与人类结直肠癌无关。

Oxidative polymorphism of debrisoquine is not related to human colo-rectal cancer.

作者信息

Ladero J M, Benítez J, González J F, Vargas E, Díaz-Rubio M

机构信息

Department of Medicine, Universidad Complutense, Madrid, Spain.

出版信息

Eur J Clin Pharmacol. 1991;40(5):525-7. doi: 10.1007/BF00315234.

DOI:10.1007/BF00315234

PMID:1884729

Abstract

The oxidative polymorphism of debrisoquine (DBQ) has been determined in 89 patients with colo-rectal cancer and in 556 normal control subjects. Four patients and 34 controls, with a metabolic ratio greater than 12.6, were classified as poor metabolisers of DBQ (n.s.). No difference was found in the distribution of the frequencies of the MR of DBQ between patients and controls. It is concluded that polymorphic oxidation of DBQ is not related to the risk of developing colo-rectal cancer in human beings.

摘要

已对89例结直肠癌患者和556名正常对照者进行了异喹胍（DBQ）氧化多态性测定。4例患者和34名对照者的代谢比值大于12.6，被归类为DBQ慢代谢者（无统计学意义）。患者与对照者之间DBQ代谢比值频率分布无差异。结论是，DBQ的多态性氧化与人类患结直肠癌的风险无关。